Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of California, San Francisco
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Ohio State University Comprehensive Cancer Center
Stanford University
Mayo Clinic
Children's Oncology Group
National Cancer Institute (NCI)
OHSU Knight Cancer Institute
City of Hope Medical Center
Mayo Clinic
City of Hope Medical Center
Emory University
Mayo Clinic
Mayo Clinic
Mayo Clinic
NRG Oncology